Clinical Trial

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-08-31; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03271632
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23